Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood-Based Control Monitors Immunosuppressant Drug Test Procedures

By Labmedica staff writers
Posted on 17 Jan 2008
A whole blood immunosuppressant control was developed for use as an assayed quality control material to monitor the precision of immunosuppressant drug test procedures in the clinical laboratory from low to very high concentrations. More...


Immunosuppressant drugs are typically used in transplant therapy to help minimize organ rejection. They are also to treat severe skin disorders such as psoriasis and other diseases such as rheumatoid arthritis, Crohn's disease (chronic inflammation of the digestive tract), and patchy hair loss (alopecia areata). Some of these conditions are autoimmune diseases, indicating that the immune system is acting against the body itself.

The new third party, human blood-based control, called Lyphocheck, offers controls for five different immunosuppressive drugs including cyclosporine, tacrolimus, and sirolimus. It can be used with immunoassay or chromatographic techniques.

Lyphocheck was developed by Bio-Rad Laboratories (Hercules, CA, USA), a manufacturer and distributor of clinical diagnostic and life science products. Being a whole blood-based material, Lyphocheck can be processed in the same manner as patient samples, ensuring quality on an ongoing basis.

The Unity Interlaboratory Program and the Unity Real Time, an expert data management software system designed to improve the effectiveness of quality control processes, are available for use with Lyphochek.


Related Links:
Bio-Rad Laboratories

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.